Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Lab Invest. 2020 Oct 9;101(2):204–217. doi: 10.1038/s41374-020-00494-1

Figure 6. Characterization of IPMN tumor organoids by DNA sequencing.

Figure 6.

Oncoprint demonstrates that genes known to be mutated in IPMN tumors (KRAS, PTEN, PIK3CA, GNAS, RNF43, and BRAF) are mutated in a subset of paired IPMN parental tumor (T) and PDO samples from pathologically-confirmed low-grade (T002, T0002, T0246) and moderate-grade (T022) IPMN cases. Red boxes indicate protein-altering mutations, and black boxes indicate protein-truncating mutations.